Towards modification of Medicago truncatula epigenome: genome editing with engineered nucleases

Periodic drought is the primary limitation of plant growth and crop yield. The rise of water demand caused by the increase in world population and climate change, leads to one of the biggest challenges of modern agriculture: to increase food and feed production. De novo DNA methylation is a process regulated by small interfering RNA (siRNAs), which play a role in plant response and adaptation to abiotic stress. In the particular case of water deficit, growing evidences suggest a link between the siRNA pathways and drought response in the model legume Medicago truncatula. As a first step to understand the role of DNA methylation under water stress, we have set up several bioinformatics and molecular methodologies allowing the design of Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 systems and the assembly of TALENs (transcription activator-like effector nucleases), to target both dicer-like 3 (MtDCL3) and RNA-Dependent RNA polymerase (MtRDR2), enzymes of the RNA-directed DNA methylation pathway. TALENs efficiency was evaluated prior to plant transformation by a yeast-based assay using two different strategies to test TALENs activity: Polyacrylamide gel electrophoresis (PAGE) and Single strand conformation polymorphisms (SSCP). In this assay, yeast cells triple transformation emerged as good and rapid alternative to laborious yeast mating strategies. PAGE analysis might be a valuable tool to test TALENs efficacy in vivo if we could increase TALENs activity. SSCP-based approach proved to be ineffective due to the generation of several false positives. TALENs and CRISPR/Cas9 system constructed and designed in this work will in the future certainly enable the successful disruption of DCL3 and RDR2 genes and shed the light on the relationship between plant stress resistance and epigenetic regulation mediated by siRNAs in M.truncatula.

Improving the early diagnostic of prostate cancer by multiple biomarker detection with new biosensing devices

Prostate cancer (PCa) is the most common form of cancer in men, in Europe (World Health Organization data). The most recent statistics, in Portuguese territory, confirm this scenario, which states that about 50% of Portuguese men may suffer from prostate cancer and 15% of these will die from this condition. Its early detection is therefore fundamental. This is currently being done by Prostate Specific Antigen (PSA) screening in urine but false positive and negative results are quite often obtained and many patients are sent to unnecessary biopsy procedures. This early detection protocol may be improved, by the development of point-of-care cancer detection devices, not only to PSA but also to other biomarkers recently identified. Thus, the present work aims to screen several biomarkers in cultured human prostate cell lines, serum and urine samples, developing low cost sensors based on new synthetic biomaterials. Biomarkers considered in this study are the following: prostate specific antigen (PSA), annexin A3 (ANXA3), microseminoprotein-beta (MSMB) and sarcosine (SAR). The biomarker recognition may occurs by means of molecularly imprinted polymers (MIP), which are a kind of plastic antibodies, and enzymatic approaches. The growth of a rigid polymer, chemically stable, using the biomarker as a template allows the synthesis of the plastic antibody. MIPs show high sensitivity/selectivity and present much longer stability and much lower price than natural antibodies. This nanostructured material was prepared on a carbon solid. The interaction between the biomarker and the sensing-material produces electrical signals generating quantitative or semi-quantitative data. These devices allow inexpensive and portable detection in point-of-care testing.

Efeito de um resultado falso positivo da leitura da mamografia na não participação no rastreio do cancro da mama : estudo de coorte histórico de um rastreio de base populacional da região de saúde do centro em Portugal

RESUMO - Introdução: O cancro da mama é uma das principais causas de mortalidade por doença oncológica. O rastreio contribui para o aumento da sobrevivência, mas apresenta riscos como a obtenção de um resultado falso positivo com efeitos controversos sobre a participação subsequente. Métodos: Realizou-se um estudo de coorte histórico (2006-2012) de 170.835 mulheres com 45-67 anos, elegíveis para o programa de rastreio do cancro da mama da ARSC,IP. Calcularam-se as medidas de efeito de um falso positivo da leitura na não participação na volta consecutiva de rastreio do cancro da mama, e a associação entre o evento em estudo e factores sociodemográficos, relacionados com o rastreio e com a anamnese, através de análise de regressão de Poisson. Resultados: A incidência de não participação foi 12,13%. A exposição a falso positivo da leitura aumentou 8,01% o risco absoluto de não participação. O falso positivo da leitura da mamografia revelou-se um factor de risco para a não participação (RRa=1,17; IC 1,10-1,25). O efeito protector da existência de participações anteriores foi superior ao efeito dos factores de risco identificados. Identificaram-se outros factores de risco e de protecção. Discussão: De acordo com os factores de risco e de protecção identificados recomendaram-se alterações à operacionalização do programa de rastreio, a manutenção das estatégias adequadas e a realização de estudos futuros para avaliar o efeito de outros factores não incluídos neste estudo. A comunicação do risco associado a um resultado anormal da mamografia é importante para diminuir a ansiedade consequente ao rastreio, devendo ser oferecidas intervenções que promovam a participação no rastreio.